A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The purpose of this study is to evaluate the efficacy and safety of JNJ-64304500 as add-on therapy to standard of care (SOC) biologic treatment with anti-tumor necrosis factor alpha or anti-interleukin 12/23 inhibitors in participants with active Crohn\'s disease in response but not remission to SOC biologic therapy.
Epistemonikos ID: 790b6b11fe4977e83a54611d1ba0c52e0d564185
First added on: May 07, 2024